Anti-IL-31 receptor antibody is shown to be a potential therapeutic option for treating itch and dermatitis in mice

British Journal of Pharmacology

Volumn 171, Issue 22, 2014, Pages 5049-5058

  Kasutani, K ^a,b   Fujii, E ^b   Ohyama, S ^b   Adachi, H ^b   Hasegawa, M ^b   Kitamura, H ^b   Yamashita, N ^a  

^a MUSASHINO UNIVERSITY   (Japan)

^b CHUGAI PHARMACEUTICAL CO LTD   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

BM 095; DEXAMETHASONE; INTERLEUKIN 31; INTERLEUKIN 31 RECEPTOR ALPHA NEUTRALIZING ANTIBODY; MONOCLONAL ANTIBODY; NALOXONE; NEUTRALIZING ANTIBODY; TACROLIMUS; TERFENADINE; UNCLASSIFIED DRUG; ANTIALLERGIC AGENT; IL31RA PROTEIN, MOUSE; INTERLEUKIN DERIVATIVE; INTERLEUKIN RECEPTOR; INTERLEUKIN-31, MOUSE; RECOMBINANT PROTEIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIINFLAMMATORY ACTIVITY; ARTICLE; ATOPIC DERMATITIS; CHRONIC DISEASE; EAR EDEMA; FEMALE; MOUSE; NONHUMAN; PHENOTYPE; PRURITUS; SCRATCHING; ANIMAL; BAGG ALBINO MOUSE; DERMATITIS, ATOPIC; IMMUNOLOGY;

ANIMALS; ANTI-ALLERGIC AGENTS; ANTIBODIES, MONOCLONAL; DERMATITIS, ATOPIC; FEMALE; INTERLEUKINS; MICE, INBRED BALB C; PRURITUS; RECEPTORS, INTERLEUKIN; RECOMBINANT PROTEINS;

EID: 84915818539     PISSN: 00071188     EISSN: 14765381     Source Type: Journal    
DOI: 10.1111/bph.12823     Document Type: Article

References (58)

1. Alexander SPH, Benson HE, Faccenda E, Pawson AJ, Sharman JL, Spedding M et al. (2013a). The Concise Guide to PHARMACOLOGY 2013/14: G protein-coupled receptors. Br J Pharmacol 170: 1459-1581.
2. Alexander SPH, Benson HE, Faccenda E, Pawson AJ, Sharman JL, Spedding M et al. (2013b). The Concise Guide to PHARMACOLOGY 2013/14: Catalytic receptors. Br J Pharmacol 170: 1676-1705.
3. Arai I, Tsuji M, Takeda H, Akiyama N, Saito S (2013). A single dose of interleukin-31 (IL-31) causes continuous itch-associated scratching behaviour in mice. Exp Dermatol 22: 669-671.
4. Assmann T, Homey B, Ruzicka T (2001). Topical tacrolimus for the treatment of inflammatory skin diseases. Expert Opin Pharmacother 2: 1167-1175.
5. Bando T, Morikawa Y, Komori T, Senba E (2006). Complete overlap of interleukin-31 receptor A and oncostatin M receptor beta in the adult dorsal root ganglia with distinct developmental expression patterns. Neuroscience 142: 1263-1271.
6. Baron R, Schwarz K, Kleinert A, Schattschneider J, Wasner G (2001). Histamine-induced itch converts into pain in neuropathic hyperalgesia. Neuroreport 12: 3475-3478.
7. Bernstein JE, Swift RM, Soltani K, Lorincz AL (1982). Antipruritic effect of an opiate antagonist, naloxone hydrochloride. J Invest Dermatol 78: 82-83.
8. Bilsborough J, Leung DY, Maurer M, Howell M, Boguniewicz M, Yao L et al. (2006). IL-31 is associated with cutaneous lymphocyte antigen-positive skin homing T cells in patients with atopic dermatitis. J Allergy Clin Immunol 117: 418-425.
9. Cheung PF, Wong CK, Ho AW, Hu S, Chen DP, Lam CW (2010). Activation of human eosinophils and epidermal keratinocytes by Th2 cytokine IL-31: implication for the immunopathogenesis of atopic dermatitis. Int Immunol 22: 453-467.
10. Cornelissen C, Marquardt Y, Czaja K, Wenzel J, Frank J, Luscher-Firzlaff J et al. (2012). IL-31 regulates differentiation and filaggrin expression in human organotypic skin models. J Allergy Clin Immunol 129: 426-433, 433, e421-e428.
11. Dillon SR, Sprecher C, Hammond A, Bilsborough J, Rosenfeld-Franklin M, Presnell SR et al. (2004). Interleukin 31, a cytokine produced by activated T cells, induces dermatitis in mice. Nat Immunol 5: 752-760.
12. Ezzat MH, Hasan ZE, Shaheen KY (2011). Serum measurement of interleukin-31 (IL-31) in paediatric atopic dermatitis: elevated levels correlate with severity scoring. J Eur Acad Dermatol Venereol 25: 334-339.
13. Fei M, Wu X, Xu Q (2005). Astilbin inhibits contact hypersensitivity through negative cytokine regulation distinct from cyclosporin A. J Allergy Clin Immunol 116: 1350-1356.
14. Finlay AY (2001). Quality of life in atopic dermatitis. J Am Acad Dermatol 45 (1 Suppl.): S64-S66.
15. Gonzales AJ, Humphrey WR, Messamore JE, Fleck TJ, Fici GJ, Shelly JA et al. (2013). Interleukin-31: its role in canine pruritus and naturally occurring canine atopic dermatitis. Vet Dermatol 24: 48-53, e11-e42.
16. Greaves MW, Khalifa N (2004). Itch: more than skin deep. Int Arch Allergy Immunol 135: 166-172.
17. Grimstad O, Sawanobori Y, Vestergaard C, Bilsborough J, Olsen UB, Gronhoj-Larsen C et al. (2009). Anti-interleukin-31-antibodies ameliorate scratching behaviour in NC/Nga mice: a model of atopic dermatitis. Exp Dermatol 18: 35-43.
18. Handwerker HO, Forster C, Kirchhoff C (1991). Discharge patterns of human C-fibers induced by itching and burning stimuli. J Neurophysiol 66: 307-315.
19. Hanifin JM (1999). Diagnostic criteria for atopic dermatitis: consider the context. Arch Dermatol 135: 1551.
20. Hanifin JM, Tofte SJ (1999). Update on therapy of atopic dermatitis. J Allergy Clin Immunol 104 (3 Pt 2): S123-S125.
21. Hawro T, Saluja R, Weller K, Altrichter S, Metz M, Maurer M (2014). Interleukin-31 does not induce immediate itch in atopic dermatitis patients and healthy controls after skin challenge. Allergy 69: 113-117.
22. Inagaki N, Igeta K, Kim JF, Nagao M, Shiraishi N, Nakamura N et al. (2002). Involvement of unique mechanisms in the induction of scratching behavior in BALB/c mice by compound 48/80. Eur J Pharmacol 448: 175-183.
23. Inagaki N, Igeta K, Shiraishi N, Kim JF, Nagao M, Nakamura N et al. (2003). Evaluation and characterization of mouse scratching behavior by a new apparatus, MicroAct. Skin Pharmacol Appl Skin Physiol 16: 165-175.
24. Inoue Y, Isobe M, Shiohara T, Goto Y, Hayashi H (2002). Protective and curative effects of topically applied CX-659S, a novel diaminouracil derivative, on chronic picryl chloride-induced contact hypersensitivity responses. Br J Dermatol 147: 675-682.
25. Kasraie S, Niebuhr M, Werfel T (2010). Interleukin (IL)-31 induces pro-inflammatory cytokines in human monocytes and macrophages following stimulation with staphylococcal exotoxins. Allergy 65: 712-721.
26. Kido M, Takeuchi S, Esaki H, Hayashida S, Furue M (2010). Scratching behavior does not necessarily correlate with epidermal nerve fiber sprouting or inflammatory cell infiltration. J Dermatol Sci 58: 130-135.
27. Kilkenny C, Browne W, Cuthill IC, Emerson M, Altman DG (2010). Animal research: reporting in vivo experiments: the ARRIVE guidelines. Br J Pharmacol 160: 1577-1579.
28. Kim HO, Lee CH, Ahn HK, Park CW (2009). Effects of tacrolimus ointment on the expression of substance P, nerve growth factor, and neurotrophin-3 in atopic dermatitis. Int J Dermatol 48: 431-438.
29. Kitagaki H, Fujisawa S, Watanabe K, Hayakawa K, Shiohara T (1995). Immediate-type hypersensitivity response followed by a late reaction is induced by repeated epicutaneous application of contact sensitizing agents in mice. J Invest Dermatol 105: 749-755.
30. Kitagaki H, Ono N, Hayakawa K, Kitazawa T, Watanabe K, Shiohara T (1997). Repeated elicitation of contact hypersensitivity induces a shift in cutaneous cytokine milieu from a T helper cell type 1 to a T helper cell type 2 profile. J Immunol 159: 2484-2491.
31. Klein PA, Clark RA (1999). An evidence-based review of the efficacy of antihistamines in relieving pruritus in atopic dermatitis. Arch Dermatol 135: 1522-1525.
32. Koblenzer CS (1999). Itching and the atopic skin. J Allergy Clin Immunol 104 (3 Pt 2): S109-S113.
33. Konishi H, Tsutsui H, Murakami T, Yumikura-Futatsugi S, Yamanaka K, Tanaka M et al. (2002). IL-18 contributes to the spontaneous development of atopic dermatitis-like inflammatory skin lesion independently of IgE/stat6 under specific pathogen-free conditions. Proc Natl Acad Sci U S A 99: 11340-11345.
34. McGrath J, Drummond G, McLachlan E, Kilkenny C, Wainwright C (2010). Guidelines for reporting experiments involving animals: the ARRIVE guidelines. Br J Pharmacol 160: 1573-1576.
35. Metz M, Grundmann S, Stander S (2011). Pruritus: an overview of current concepts. Vet Dermatol 22: 121-131.
36. Monroe EW (1989). Efficacy and safety of nalmefene in patients with severe pruritus caused by chronic urticaria and atopic dermatitis. J Am Acad Dermatol 21: 135-136.
37. Neis MM, Peters B, Dreuw A, Wenzel J, Bieber T, Mauch C et al. (2006). Enhanced expression levels of IL-31 correlate with IL-4 and IL-13 in atopic and allergic contact dermatitis. J Allergy Clin Immunol 118: 930-937.
38. Niyonsaba F, Ushio H, Hara M, Yokoi H, Tominaga M, Takamori K et al. (2010). Antimicrobial peptides human beta-defensins and cathelicidin LL-37 induce the secretion of a pruritogenic cytokine IL-31 by human mast cells. J Immunol 184: 3526-3534.
39. Novak N, Bieber T, Leung DY (2003). Immune mechanisms leading to atopic dermatitis. J Allergy Clin Immunol 112 (6 Suppl.): S128-S139.
40. Okayama Y, Benyon RC, Lowman MA, Church MK (1994). In vitro effects of H1-antihistamines on histamine and PGD2 release from mast cells of human lung, tonsil, and skin. Allergy 49: 246-253.
41. Paus R, Schmelz M, Biro T, Steinhoff M (2006). Frontiers in pruritus research: scratching the brain for more effective itch therapy. J Clin Invest 116: 1174-1186.
42. Pawson AJ, Sharman JL, Benson HE, Faccenda E, Alexander SP, Buneman OP et al. (2014). The IUPHAR/BPS Guide to PHARMACOLOGY: an expert-driven knowledgebase of drug targets and their ligands. Nucl Acids Res 42 (Database Issue): D1098-106.
43. Raap U, Wichmann K, Bruder M, Stander S, Wedi B, Kapp A et al. (2008). Correlation of IL-31 serum levels with severity of atopic dermatitis. J Allergy Clin Immunol 122: 421-423.
44. Sengoku T, Kishi S, Sakuma S, Ohkubo Y, Goto T (2000). FK506 inhibition of histamine release and cytokine production by mast cells and basophils. Int J Immunopharmacol 22: 189-201.
45. Sonkoly E, Muller A, Lauerma AI, Pivarcsi A, Soto H, Kemeny L et al. (2006). IL-31: a new link between T cells and pruritus in atopic skin inflammation. J Allergy Clin Immunol 117: 411-417.
46. Stander S, Steinhoff M (2002). Pathophysiology of pruritus in atopic dermatitis: an overview. Exp Dermatol 11: 12-24.
47. Steinhoff M, Bienenstock J, Schmelz M, Maurer M, Wei E, Biro T (2006). Neurophysiological, neuroimmunological, and neuroendocrine basis of pruritus. J Invest Dermatol 126: 1705-1718.
48. Takano N, Arai I, Kurachi M (2003). Analysis of the spontaneous scratching behavior by NC/Nga mice: a possible approach to evaluate antipruritics for subjects with atopic dermatitis. Eur J Pharmacol 471: 223-228.
49. Takano N, Arai I, Hashimoto Y, Kurachi M (2004). Evaluation of antipruritic effects of several agents on scratching behavior by NC/Nga mice. Eur J Pharmacol 495: 159-165.
50. Takaoka A, Arai I, Sugimoto M, Yamaguchi A, Tanaka M, Nakaike S (2005). Expression of IL-31 gene transcripts in NC/Nga mice with atopic dermatitis. Eur J Pharmacol 516: 180-181.
51. Takaoka A, Arai I, Sugimoto M, Honma Y, Futaki N, Nakamura A et al. (2006). Involvement of IL-31 on scratching behavior in NC/Nga mice with atopic-like dermatitis. Exp Dermatol 15: 161-167.
52. Wahlgren CF (1991). Itch and atopic dermatitis: clinical and experimental studies. Acta Derm Venereol Suppl (Stockh) 165: 1-53.
53. Williams HC, Burney PG, Pembroke AC, Hay RJ (1994). The U.K. working party's diagnostic criteria for atopic dermatitis. III. Independent hospital validation. Br J Dermatol 131: 406-416.
54. Xu H, DiIulio NA, Fairchild RL (1996). T cell populations primed by hapten sensitization in contact sensitivity are distinguished by polarized patterns of cytokine production: interferon gamma-producing (Tc1) effector CD8+ T cells and interleukin (Il) 4/Il-10-producing (Th2) negative regulatory CD4+ T cells. J Exp Med 183: 1001-1012.
55. Yamaoka K, Okayama Y, Kaminuma O, Katayama K, Mori A, Tatsumi H et al. (2009). Proteomic Approach to FcepsilonRI aggregation-initiated signal transduction cascade in human mast cells. Int Arch Allergy Immunol 149 (Suppl. 1): 73-76.
56. Yamashita H, Michibata Y, Mizukami H, Ogihara Y, Morita A, Nose M (2005). Dermal mast cells play a central role in the incidence of scratching behavior in mice induced by multiple application of the hapten, 2,4,6-trinitrochlorobenzene. Exp Dermatol 14: 438-444.
57. Yamashita H, Makino T, Mizukami H, Nose M (2007). Pharmacological characterization of a chronic pruritus model induced by multiple application of 2,4,6-trinitrochlorobenzene in NC mice. Eur J Pharmacol 563: 233-239.
58. Zhang Q, Putheti P, Zhou Q, Liu Q, Gao W (2008). Structures and biological functions of IL-31 and IL-31 receptors. Cytokine Growth Factor Rev 19: 347-356.